- Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
-
Ko YH, Lee MA, Hong YS, Lee KS, Park HJ, Yoo IR, Kim YS, Kim YK, Jo KH, Wang YP, Lee KY, Kang JH
- KMID: 1785624
- Korean J Intern Med.
- 2007 Sep;22(3):178-185.
- doi: 10.3904/kjim.2007.22.3.178
BACKGROUND: Second-line chemotherapy offers advanced non-small cell lung cancer (NSCLC) patients a small, but significant increase in survival. Docetaxel is usually administered as a 3-week schedule, yet there is... -
- CITED
-
- Close
- SHARE
-
- Close
